CLINICAL_TRIALS
trial_result
· 2014-12-09
Clinical Trial Update: PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma [Phase 2]
Summary
A Phase 2 trial of PTK787 (vatalanib) for refractory or relapsed diffuse large B-cell lymphoma was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: David Rizzieri, MD | Conditions: Lymphoma, Large-Cell, Diffuse | Phase 2 | Status: TERMINATED